



Press Release

Lupin Launches SUPRAX[®] 400 mg Tablets in the US

BSE: 500257	NSE: LUPIN	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
-------------	------------	---------------------	----------------------

April 28, 2008, Mumbai, India

Lupin Ltd. (Lupin), announced today that its subsidiary, Lupin Pharmaceuticals Inc (LPI), has launched Suprax[®] 400 mg Tablets (Cefixime USP) in the US.

This line extension, further extends the brand franchise of Lupin's flagship anti-infective Suprax[®] (Cefixime for oral suspension 100 mg/ 5 ml and 200 mg/ 5ml)

Suprax[®] 400 mg Tablets will help Lupin to further increase its share of the \$450 Million antibiotic market for the treatment of Urinary Tract Infections. It will also extend the use of Suprax[®] to the patient population of children of the age of 12 yrs and above.

“Suprax[®] 400 mg Tablets offers an additional value proposition to Pediatricians by covering the adolescent and teenage patient population. The incidence of Urinary Tract Infections is high in children and Pediatricians are the 5th largest specialty prescribing antibiotics for this indication. We expect Suprax[®] 400 mg Tablets to add substantial value to the Suprax[®] franchise” said, Dr Kamal Sharma, Managing Director, Lupin.

Suprax[®] 400 mg Tablets will be promoted by a 60 strong specialty pediatric sales force. Lupin is also evaluating additional options of reaching out to other specialty doctors. It's efforts will be supplemented by innovative promotional campaigns.

The Suprax® brand basket now includes, Suprax® (Cefixime for oral suspension 100 mg/ 5 ml and 200 mg/ 5ml and Suprax® 400 mg tablets (Cefixime USP)

About Lupin

Lupin Pharmaceuticals, Inc is the wholly owned U.S. subsidiary of Mumbai based Lupin Limited, a leading Indian Pharmaceutical company. Lupin Limited develops, manufactures and markets a wide range of quality, affordable generic and branded generic formulations and APIs for the developed and the developing markets of the world. The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs. Twelve of Lupin's facilities have been inspected and approved by the U.S. Food & Drug Administration.

The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value added generic pharmaceuticals. Currently positioned amongst the top six pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders.

For further information please contact:

Lupin Limited:

Seema Ahuja
Head, Corporate Communications

Ph: +919920042046
022 66402323 Extn: 2531
Fax: 022 66402534
email:seemaahuja@lupinpharma.com

OR

Source Strategic Communications Pvt. Ltd.
Archana Pradhan

Ph: +919820330505
email: archanapradhan@sourcepr.com